论文部分内容阅读
目的:探讨性别因素对厄洛替尼(erlotinib)治疗晚期非小细胞肺癌疗效影响。方法:对接受过1个周期以上含铂化疗方案失败的晚期非小细胞肺癌患者,每天口服150 mg厄洛替尼直至疾病进展,观察不同性别患者厄洛替尼治疗的疗效、生存时间。采用Kaplan-Meier法分析比较两组间生存率差异。结果:2005年12月至2006年9月,共有48例入组厄洛替尼EAP(Expanded Acess Program)项目,随访截至2008年12月8日,中位随访时间为30个月。患者依从性为100%。男性组共33例,有效率为33.3%(11/33),女性组15例,有效率为33.3%(5/15),男性组与女性组之间有效率差异无显著性(P=1)。采用Kaplan-Meier法比较不同性别间的无进展时间、总生存时间差异,男性组中位无进展时间为4个月,女性组中位无进展时间为6个月,两组之间差异无显著性(P=0.301)。男性组中位生存时间为6个月,女性组中位生存时间为15个月,两组之间差异无显著性(P=0.248)。结论:对于不同性别晚期非小细胞肺癌患者,厄洛替尼均有效,且对于女性患者,可能有较长生存期,但差异无统计学意义。
Objective: To investigate the effect of gender on the efficacy of erlotinib in the treatment of advanced non-small cell lung cancer. Methods: Patients with advanced non-small cell lung cancer who had failed to receive platinum-based chemotherapy for more than one cycle were given orally with 150 mg of erlotinib daily until the disease progressed. Efficacy and survival of erlotinib in different gender were observed. Kaplan-Meier analysis was used to compare the survival rates between the two groups. Results: From December 2005 to September 2006, a total of 48 patients were enrolled in the Expanded Acess Program (EAP). The follow-up was December 8, 2008 and the median follow-up time was 30 months. Patient compliance was 100%. There were 33 males and 33.3% females, and 15 females. The effective rate was 33.3% (5/15). There was no significant difference between male and females (P = ). Kaplan-Meier method was used to compare the progression-free time and total survival time between different genders. The median progression-free time was 4 months in males and 6 months in females, with no significant difference between the two groups Sex (P = 0.301). The median survival time in males was 6 months, and the median survival time in females was 15 months. There was no significant difference between the two groups (P = 0.248). CONCLUSION: Erlotinib is effective for patients with advanced non-small cell lung cancer of different genders and may have longer survival for female patients, but the difference is not statistically significant.